{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:05:13Z","timestamp":1790186713442,"version":"4.1.0"},"reference-count":126,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:00:00Z","timestamp":1788566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001602","name":"Taighde \u00c9ireann - Research Ireland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.drudis.2026.104800","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:59:04Z","timestamp":1788969544000},"page":"104800","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effector-cell-engaging bispecific antibodies for cancer therapeutics: Engineering precision immunity"],"prefix":"10.1016","volume":"31","author":[{"given":"Amol D.","family":"Gholap","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj R.","family":"Khuspe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darshana","family":"Morankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navnath T.","family":"Hatvate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6343-527X","authenticated-orcid":false,"given":"Nanasaheb D.","family":"Thorat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104800_b0005","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/s43018-025-00990-7","article-title":"The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types","volume":"6","author":"Awada","year":"2025","journal-title":"Nat Cancer"},{"key":"10.1016\/j.drudis.2026.104800_b0010","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3390\/antib14020035","article-title":"A comprehensive review about the use of monoclonal antibodies in cancer therapy","volume":"14","author":"Justiz-Vaillant","year":"2025","journal-title":"Antibodies"},{"key":"10.1016\/j.drudis.2026.104800_b0015","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40035-025-00465-w","article-title":"Second-generation anti-amyloid monoclonal antibodies for Alzheimer\u2019s disease: current landscape and future perspectives","volume":"14","author":"Kim","year":"2025","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.drudis.2026.104800_b0020","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1523693","article-title":"Prodrug-based bispecific antibodies for cancer therapy: advances and future directions","volume":"16","author":"Ai","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2026.104800_b0025","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/cpt.3439","article-title":"Industry perspective on first\u2010in\u2010human and clinical pharmacology strategies to support clinical development of T\u2010cell engaging bispecific antibodies for cancer therapy","volume":"117","author":"Nagaraja Shastri","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2026.104800_b0030","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1016\/j.ymthe.2025.06.042","article-title":"CD19xCD3 T cell engager blinatumomab effective in refractory generalized myasthenic syndromes","volume":"33","author":"Ruck","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.drudis.2026.104800_b0035","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/bjh.70228","article-title":"Bispecific antibody combination therapies in diffuse large B\u2010cell lymphoma","volume":"208","author":"Harrop","year":"2026","journal-title":"Br J Haematol"},{"key":"10.1016\/j.drudis.2026.104800_b0040","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s12272-026-01595-z","article-title":"Bispecific antibody\u2013drug conjugates: a modular blueprint for next-generation cancer therapeutics","volume":"49","author":"Bai","year":"2026","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.drudis.2026.104800_b0045","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","article-title":"Bispecific antibodies: advancing precision oncology","volume":"10","author":"Herrera","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.drudis.2026.104800_b0050","article-title":"Evolution of bispecific and multispecific antibodies in cancer therapy","volume":"64","author":"Fontana","year":"2026","journal-title":"Lancet Reg Heal \u2013 Eur"},{"key":"10.1016\/j.drudis.2026.104800_b0055","article-title":"Mechanisms of tumor cell evasion from NK cell-mediated killing and advances in NK cell-based cancer immunotherapy","volume":"4","author":"Zheng","year":"2026","journal-title":"Pharm Sci Adv"},{"key":"10.1016\/j.drudis.2026.104800_b0060","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","article-title":"Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches","volume":"10","author":"Tufail","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.drudis.2026.104800_b0065","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s40291-024-00734-w","article-title":"Clinical progresses and challenges of bispecific antibodies for the treatment of solid tumors","volume":"28","author":"Gu","year":"2024","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.drudis.2026.104800_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2025.465722","article-title":"Trends and challenges in bispecific antibody production","volume":"1744","author":"Karbyshev","year":"2025","journal-title":"J Chromatogr A"},{"key":"10.1016\/j.drudis.2026.104800_b0075","doi-asserted-by":"crossref","first-page":"5838","DOI":"10.3390\/ijms26125838","article-title":"Bispecific antibodies in solid tumors: advances and challenges","volume":"26","author":"Shan","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104800_b0080","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1016\/j.apsb.2023.05.023","article-title":"Bispecific antibodies in cancer therapy: target selection and regulatory requirements","volume":"13","author":"Sun","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.drudis.2026.104800_b0085","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3390\/ph19081245","article-title":"Functional characteristics derived from the structural design of bispecific antibodies","volume":"19","author":"Han","year":"2026","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.drudis.2026.104800_b0090","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2025.1652047","article-title":"Reprogramming cancer immunity with next-generation combination therapies","volume":"13","author":"Kyriakidis","year":"2025","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.drudis.2026.104800_b0095","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41577-024-01111-8","article-title":"Cancer immune evasion, immunoediting and intratumour heterogeneity","volume":"25","author":"Roerden","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.drudis.2026.104800_b0100","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1038\/s41388-025-03458-1","article-title":"Immunometabolism of regulatory T cells in cancer","volume":"44","author":"Saravia","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2026.104800_b0105","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41392-025-02332-6","article-title":"Immunological synapse: structures, molecular mechanisms and therapeutic implications in disease","volume":"10","author":"Chao","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.drudis.2026.104800_b0110","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s12967-025-06291-y","article-title":"New insights on anti-tumor immunity of CD8+ T cells: cancer stem cells, tumor immune microenvironment and immunotherapy","volume":"23","author":"Lin","year":"2025","journal-title":"J Transl Med"},{"key":"10.1016\/j.drudis.2026.104800_b0115","doi-asserted-by":"crossref","first-page":"20600","DOI":"10.1038\/s41598-025-07120-4","article-title":"TRPV1 inhibition sensitizes tumors to PD-1 blockade by reversing resistance to CTL-mediated killing","volume":"15","author":"Son","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2026.104800_b0120","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.trecan.2024.07.009","article-title":"CD4+ T cells in antitumor immunity","volume":"10","author":"Montauti","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.drudis.2026.104800_b0125","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s12967-025-07288-3","article-title":"Cytotoxic T lymphocytes and their dual role in modulating blood-brain barrier integrity in immune-mediated neurological pathologies","volume":"24","author":"Li","year":"2025","journal-title":"J Transl Med"},{"key":"10.1016\/j.drudis.2026.104800_b0130","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1548292","article-title":"ADCC: the rock band led by therapeutic antibodies, tumor and immune cells","volume":"16","author":"Vincken","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2026.104800_b0135","doi-asserted-by":"crossref","DOI":"10.1093\/jmcb\/mjaf059","article-title":"Fc\u03b5RI\u03b3 reinforces double-negative T cell-mediated antibody-dependent cellular cytotoxicity against tumor cells","author":"Shao","year":"2026","journal-title":"J Mol Cell Biol"},{"key":"10.1016\/j.drudis.2026.104800_b0140","first-page":"21","article-title":"The novel CD16A\/anti-CD3 bifunctional protein, eCD16A\/anti-CD3-BFP, redirects T cell cytotoxicity toward antibody-bound target cells","author":"Lin","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.drudis.2026.104800_b0145","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural killer cells in antitumour adoptive cell immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.drudis.2026.104800_b0150","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s12967-022-03437-0","article-title":"Natural killer cells: a promising immunotherapy for cancer","volume":"20","author":"Chu","year":"2022","journal-title":"J Transl Med"},{"key":"10.1016\/j.drudis.2026.104800_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115332","article-title":"Immunometabolism of tumor-associated macrophages: a therapeutic perspective","volume":"220","author":"Karimova","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.drudis.2026.104800_b0160","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","article-title":"Macrophages in immunoregulation and therapeutics","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.drudis.2026.104800_b0165","doi-asserted-by":"crossref","first-page":"18916","DOI":"10.1038\/s41598-025-03825-8","article-title":"Construction and validation of antibody dependent cell phagocytosis related risk model in breast cancer","volume":"15","author":"Jiang","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2026.104800_b0170","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1016\/j.devcel.2024.07.017","article-title":"Prior Fc receptor activation primes macrophages for increased sensitivity to IgG via long-term and short-term mechanisms","volume":"59","author":"Bond","year":"2024","journal-title":"Dev Cell"},{"key":"10.1016\/j.drudis.2026.104800_b0175","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae720","article-title":"Dengue virus structural proteins are expressed on the surface of DENV-infected cells and are a target for antibody-dependent cellular phagocytosis","volume":"12","author":"Waldran","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.drudis.2026.104800_b0180","doi-asserted-by":"crossref","first-page":"S615","DOI":"10.1016\/j.ajt.2025.07.1431","article-title":"Beyond neutralization: transplant recipients display deficient antibody-dependent cellular phagocytosis (ADCP) responses following SARS-CoV-2 vaccination","volume":"25","author":"Ferro","year":"2025","journal-title":"Am J Transplant"},{"key":"10.1016\/j.drudis.2026.104800_b0185","doi-asserted-by":"crossref","first-page":"9915","DOI":"10.1038\/s41467-025-64862-5","article-title":"A monoclonal antibody that inhibits the shedding of CD16a and CD16b and promotes antibody-dependent cellular cytotoxicity against tumors","volume":"16","author":"da Silva Bortoleti","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104800_b0190","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-24-3694","article-title":"Cell therapies and bispecific engagers: redefining strategies against checkpoint resistance","author":"L\u00e4ubli","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104800_b0195","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41551-025-01450-4","article-title":"Bispecific killer cell engager-secreting CAR-T cells redirect natural killer specificity to enhance antitumour responses","volume":"10","author":"Fan","year":"2025","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.drudis.2026.104800_b0200","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1679092","article-title":"Bispecific immunotherapy based on antibodies, T-cell receptors, and aptamers: mechanisms of action, adverse effects, and future perspectives","volume":"16","author":"Lopatnikova","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2026.104800_b0205","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/antib14030052","article-title":"Fragment-based immune cell engager antibodies in treatment of cancer, infectious and autoimmune diseases: lessons and insights from clinical and translational studies","volume":"14","author":"Yang","year":"2025","journal-title":"Antibodies"},{"key":"10.1016\/j.drudis.2026.104800_b0210","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3390\/biom10030360","article-title":"Bispecific antibodies and antibody\u2013drug conjugates for cancer therapy: technological considerations","volume":"10","author":"Shim","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.drudis.2026.104800_b0215","doi-asserted-by":"crossref","first-page":"708","DOI":"10.4062\/biomolther.2024.146","article-title":"Mechanism of action and pharmacokinetics of approved bispecific antibodies","volume":"32","author":"Choi","year":"2024","journal-title":"Biomol Ther (Seoul)"},{"key":"10.1016\/j.drudis.2026.104800_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.pep.2025.106836","article-title":"Study on the hole and knob related impurities in the purification of bispecific antibodies","volume":"238","author":"Chen","year":"2026","journal-title":"Protein Expr Purif"},{"key":"10.1016\/j.drudis.2026.104800_b0225","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood-2018-99-115957","article-title":"Duobody-CD3xCD20 shows unique and potent preclinical anti-tumor activity in vitro and in vivo, and is being evaluated clinically in patients with B-cell malignancies","volume":"132","author":"Hiemstra","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2026.104800_b0230","first-page":"1","article-title":"Discovery of a common light chain bispecific antibody targeting PD-1 and PD-L1 by Hybridoma-to-Phage-to-Yeast (H2PtY) platform","volume":"8","author":"Liu","year":"2025","journal-title":"Antib Ther"},{"key":"10.1016\/j.drudis.2026.104800_b0235","first-page":"26","article-title":"Strategies for the generation of bispecific antibodies","author":"Yuan","year":"2025","journal-title":"Chembiochem"},{"key":"10.1016\/j.drudis.2026.104800_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2026.218578","article-title":"Bispecific antibodies for cancer therapy: evolution of structural formats and co-targeting strategies from wet-lab to AI-driven in silico modeling","volume":"653","author":"Fan","year":"2026","journal-title":"Cancer Lett"},{"key":"10.1016\/j.drudis.2026.104800_b0245","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3390\/pharmaceutics18020269","article-title":"Impact of neonatal Fc receptor on transferrin receptor antibody fusion protein pharmacokinetics","volume":"18","author":"Oyegbesan","year":"2026","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2026.104800_b0250","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ymeth.2018.09.010","article-title":"Bispecific applications of non-immunoglobulin scaffold binders","volume":"154","author":"Hober","year":"2019","journal-title":"Methods"},{"key":"10.1016\/j.drudis.2026.104800_b0255","doi-asserted-by":"crossref","first-page":"10082","DOI":"10.3390\/ijms262010082","article-title":"Engineering bispecific peptides for precision immunotherapy and beyond","volume":"26","author":"Ding","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104800_b0260","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13045-021-01084-4","article-title":"Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies","volume":"14","author":"Tian","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.drudis.2026.104800_b0265","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.omto.2019.02.004","article-title":"Single-chain variable fragment-based bispecific antibodies: hitting two targets with one sophisticated arrow","volume":"14","author":"Ahamadi-Fesharaki","year":"2019","journal-title":"Mol Ther \u2013 Oncolytics"},{"key":"10.1016\/j.drudis.2026.104800_b0270","doi-asserted-by":"crossref","first-page":"5686","DOI":"10.3390\/ijms23105686","article-title":"Bispecific antibody-based immune-cell engagers and their emerging therapeutic targets in cancer immunotherapy","volume":"23","author":"Shin","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104800_b0275","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.str.2025.03.006","article-title":"Disulfide-stabilized diabodies enable near-atomic cryo-EM imaging of small proteins: a case study of the bacterial Na+\/citrate symporter CitS","volume":"33","author":"Kim","year":"2025","journal-title":"Structure"},{"key":"10.1016\/j.drudis.2026.104800_b0280","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1080\/19420862.2015.1029216","article-title":"A tetravalent bispecific TandAb (CD19\/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19 + tumor cells","volume":"7","author":"Reusch","year":"2015","journal-title":"MAbs"},{"key":"10.1016\/j.drudis.2026.104800_b0285","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1080\/19420862.2016.1197457","article-title":"The use of CrossMAb technology for the generation of bi- and multispecific antibodies","volume":"8","author":"Klein","year":"2016","journal-title":"MAbs"},{"key":"10.1016\/j.drudis.2026.104800_b0290","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3390\/antib9040064","article-title":"Fc-engineering for modulated effector functions \u2013 improving antibodies for cancer treatment","volume":"9","author":"Liu","year":"2020","journal-title":"Antibodies"},{"key":"10.1016\/j.drudis.2026.104800_b0295","doi-asserted-by":"crossref","DOI":"10.1053\/j.seminhematol.2025.11.002","article-title":"Trispecific T cell engagers in hematological malignancies: Advancing beyond bispecific antibodies","author":"Koh","year":"2025","journal-title":"Semin Hematol"},{"key":"10.1016\/j.drudis.2026.104800_b0300","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3390\/cancers13020287","article-title":"Overcoming challenges for CD3-bispecific antibody therapy in solid tumors","volume":"13","author":"Middelburg","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drudis.2026.104800_b0305","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.3390\/biomedicines10081843","article-title":"The generation of dual-targeting fusion protein PD-L1\/CD47 for the inhibition of triple-negative breast cancer","volume":"10","author":"Bian","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.drudis.2026.104800_b0310","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2026.2622746","article-title":"Expanding the horizons of cancer therapy with next-generation 4-1BB agonists: a review of molecular and clinical strategies to maximize efficacy and ensure safety","volume":"18","author":"You","year":"2026","journal-title":"MAbs"},{"key":"10.1016\/j.drudis.2026.104800_b0315","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.3390\/cancers15102824","article-title":"T-cell engagers in solid cancers \u2013 current landscape and future directions","volume":"15","author":"Shanshal","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drudis.2026.104800_b0320","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12943-026-02685-8","article-title":"Landscape of T-cell bispecific antibodies in cancer therapy: therapeutic strategies, challenges and future prospection","volume":"25","author":"Jiao","year":"2026","journal-title":"Mol Cancer"},{"key":"10.1016\/j.drudis.2026.104800_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2025.113817","article-title":"Theoretical and practical considerations for validating antigen-specific B cell ImmunoSpot assays","volume":"537","author":"Lehmann","year":"2025","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.drudis.2026.104800_b0330","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.euo.2024.09.015","article-title":"Prostate-specific membrane antigen positron emission tomography before reaching the phoenix criteria for biochemical recurrence of prostate cancer after radiotherapy: earlier detection of recurrences","volume":"8","author":"van Altena","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.drudis.2026.104800_b0335","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40265-024-02115-3","article-title":"Immunogenicity of therapeutic antibodies used for inflammatory bowel disease: treatment and clinical considerations","volume":"85","author":"Nielsen","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2026.104800_b0340","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/s41577-025-01150-9","article-title":"New insights into antibody structure with implications for specificity, variable region restriction and isotype choice","volume":"25","author":"McConnell","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.drudis.2026.104800_b0345","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10238-026-02057-y","article-title":"The safety and efficacy of bispecific T-cell engagers (TCEs) in patients with glioma","volume":"26","author":"Robat-Jazi","year":"2026","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.drudis.2026.104800_b0350","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1080\/17460441.2025.2522088","article-title":"The impact of CD3 affinity-attenuation on T cell engaging bispecific antibodies: is it really that simple?","volume":"20","author":"Abdelmotaleb","year":"2025","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.drudis.2026.104800_b0355","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/s41416-025-03125-y","article-title":"T cell engagers: expanding horizons in oncology and beyond","volume":"133","author":"Albayrak","year":"2025","journal-title":"Br J Cancer"},{"key":"10.1016\/j.drudis.2026.104800_b0360","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.apsb.2024.03.027","article-title":"Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy","volume":"14","author":"Qin","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.drudis.2026.104800_b0365","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"van de Donk","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2026.104800_b0370","first-page":"15","article-title":"Effective cancer immunotherapy combining mRNA-encoded bispecific antibodies that induce polyclonal T cell engagement and PD-L1-dependent 4-1BB costimulation","author":"Hangiu","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2026.104800_b0375","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.pharmthera.2017.08.005","article-title":"T cell engaging bispecific antibody (T-BsAb): from technology to therapeutics","volume":"182","author":"Wu","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.drudis.2026.104800_b0380","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1158\/1078-0432.CCR-21-0355","article-title":"BiTE-ing into prostate cancer with bispecific T-cell engagers","volume":"27","author":"Kamat","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104800_b0385","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s11864-025-01290-z","article-title":"Targets selection for precision therapy of relapsed\/refractory multiple myeloma: the latest advancements","volume":"26","author":"Wang","year":"2025","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.drudis.2026.104800_b0390","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2443538","article-title":"Antibodies to watch in 2025","volume":"17","author":"Crescioli","year":"2025","journal-title":"MAbs"},{"key":"10.1016\/j.drudis.2026.104800_b0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2026.120115","article-title":"The role of cytokines in cytokine release syndrome (CRS) after CAR T cell therapy","volume":"1873","author":"Gabriel","year":"2026","journal-title":"Biochim Biophys Acta \u2013 Mol Cell Res"},{"key":"10.1016\/j.drudis.2026.104800_b0400","doi-asserted-by":"crossref","first-page":"7308","DOI":"10.1038\/s41598-025-91396-z","article-title":"How modulation of the tumor microenvironment drives cancer immune escape dynamics","volume":"15","author":"Shrestha","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2026.104800_b0405","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41568-025-00883-y","article-title":"Epigenetic regulation of T cell exhaustion in cancer","volume":"26","author":"Kang","year":"2026","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.drudis.2026.104800_b0410","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41392-025-02325-5","article-title":"Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments","volume":"10","author":"Xu","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.drudis.2026.104800_b0415","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/s41423-024-01253-8","article-title":"Cell-associated galectin 9 interacts with cytotoxic T cells confers resistance to tumor killing in nasopharyngeal carcinoma through autophagy activation","volume":"22","author":"Kam","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.drudis.2026.104800_b0420","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11523-026-01198-0","article-title":"Bispecific antibodies in breast cancer immunotherapy: mechanisms, advances, and translational challenges","volume":"21","author":"Brogna","year":"2026","journal-title":"Target Oncol"},{"key":"10.1016\/j.drudis.2026.104800_b0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.114203","article-title":"Advances in the clinical application of bispecific antibodies in cancer therapy","volume":"28","author":"Zhou","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.drudis.2026.104800_b0430","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1016\/j.apsb.2025.03.012","article-title":"Design and functional characterization of a tetravalent NK cell-engaging bispecific antibody with enhanced half-life for CD30+ lymphoma","volume":"15","author":"Zhao","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.drudis.2026.104800_b0435","article-title":"Enhancing NK cell-mediated tumor killing of B7-H6+ cells with bispecific antibodies targeting allosteric sites of NKp30","volume":"33","author":"Fournier","year":"2025","journal-title":"Mol Ther Oncol"},{"key":"10.1016\/j.drudis.2026.104800_b0440","article-title":"Dual T\/NK cell engagement via B7-H6-targeted bispecific antibodies and IL-15 eradicates chemo-resistant solid tumors","volume":"16","author":"Ma","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2026.104800_b0445","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s13045-021-01216-w","article-title":"Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity","volume":"14","author":"Wang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.drudis.2026.104800_b0450","first-page":"15","article-title":"Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors","author":"Whalen","year":"2023","journal-title":"MAbs"},{"key":"10.1016\/j.drudis.2026.104800_b0455","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2315640","article-title":"Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers","volume":"16","author":"Boje","year":"2024","journal-title":"MAbs"},{"key":"10.1016\/j.drudis.2026.104800_b0460","doi-asserted-by":"crossref","DOI":"10.14218\/ERHM.2022.00024","article-title":"Harnessing natural killer cell-mediated innate immune responses for cancer treatment: advances and challenges","author":"Kumar","year":"2022","journal-title":"Explor Res Hypothesis Med"},{"key":"10.1016\/j.drudis.2026.104800_b0465","doi-asserted-by":"crossref","first-page":"11272","DOI":"10.1039\/D4SC00851K","article-title":"Macrophage-engaging peptidic bispecific antibodies (pBsAbs) for immunotherapy via a facile bioconjugation strategy","volume":"15","author":"Shao","year":"2024","journal-title":"Chem Sci"},{"key":"10.1016\/j.drudis.2026.104800_b0470","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-026-76180-5","article-title":"High-throughput engineering of bispecific antibodies to enhance macrophage-mediated cytotoxicity of B-cell lymphoma","author":"Pag\u00e8s-Geli","year":"2026","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104800_b0475","first-page":"4","article-title":"Blinatumomab, a Bi-specific anti-CD19\/CD3 BiTE\u00c2\u00ae antibody for the treatment of acute lymphoblastic leukemia: perspectives and current pediatric applications","author":"Hoffman","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.drudis.2026.104800_b0480","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2018-99-118344","article-title":"Mosunetuzumab, a full-length bispecific CD20\/CD3 antibody, displays clinical activity in relapsed\/refractory B-cell non-hodgkin lymphoma (NHL): interim safety and efficacy results from a phase 1 study","volume":"132","author":"Budde","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2026.104800_b0485","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104800_b0490","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/blood-2020-139192","article-title":"REGN5458, a BCMA x CD3 bispecific monoclonal antibody, induces deep and durable responses in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"136","author":"Madduri","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2026.104800_b0495","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1158\/1078-0432.CCR-20-3725","article-title":"The PSMA-targeting half-life extended BiTE therapy AMG 160 has potent antitumor activity in preclinical models of metastatic castration-resistant prostate cancer","volume":"27","author":"Deegen","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104800_b0500","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","article-title":"A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Rothe","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2026.104800_b0505","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.3390\/cancers15071987","article-title":"Emerging targeted therapies for HER2-positive breast cancer","volume":"15","author":"Mercogliano","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drudis.2026.104800_b0510","article-title":"Bispecific antibody for lung cancer: mechanisms and clinical insights","volume":"16","author":"Chen","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2026.104800_b0515","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1158\/1078-0432.CCR-15-2710","article-title":"IL15 Trispecific Killer Engagers (TriKE) make natural killer cells specific to CD33+ targets while also inducing persistence, in vivo expansion, and enhanced function","volume":"22","author":"Vallera","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104800_b0520","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.929339","article-title":"Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages","volume":"13","author":"Zeller","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2026.104800_b0525","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.70014","article-title":"Dual CD47 and PD\u2010L1 blockade elicits anti\u2010tumor immunity by intratumoral CD8 + T cells","volume":"13","author":"Christo","year":"2024","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.drudis.2026.104800_b0530","first-page":"15","article-title":"A first-in-human study of the fibroblast activation protein\u2013targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors","author":"Melero","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.drudis.2026.104800_b0535","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12943-025-02390-y","article-title":"Bispecific antibodies: unleashing a new era in oncology treatment","volume":"24","author":"Shui","year":"2025","journal-title":"Mol Cancer"},{"key":"10.1016\/j.drudis.2026.104800_b0540","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s42003-024-06682-9","article-title":"CD3-engaging bispecific antibodies trigger a paracrine regulated wave of T-cell recruitment for effective tumor killing","volume":"7","author":"Liao","year":"2024","journal-title":"Commun Biol"},{"key":"10.1016\/j.drudis.2026.104800_b0545","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.3390\/ph14111172","article-title":"T cell bispecific antibodies: an antibody-based delivery system for inducing antitumor immunity","volume":"14","author":"Kamakura","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.drudis.2026.104800_b0550","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13036-025-00517-9","article-title":"Design of a prodrug bispecific antibody masked by a functional molecule for lymphocyte activation for cancer therapy","volume":"19","author":"Miura","year":"2025","journal-title":"J Biol Eng"},{"key":"10.1016\/j.drudis.2026.104800_b0555","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s12672-025-04195-3","article-title":"Advancing breast cancer treatment through dual targeting CAR T cell therapy","volume":"17","author":"Sheikh","year":"2025","journal-title":"Discov Oncol"},{"key":"10.1016\/j.drudis.2026.104800_b0560","first-page":"15","article-title":"Logic-gated and contextual control of immunotherapy for solid tumors: contrasting multi-specific T cell engagers and CAR-T cell therapies","author":"Nolan-Stevaux","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2026.104800_b0565","doi-asserted-by":"crossref","first-page":"12383","DOI":"10.1080\/21655979.2021.2003666","article-title":"Engineered mRNA-expressed bispecific antibody prevent intestinal cancer via lipid nanoparticle delivery","volume":"12","author":"Wu","year":"2021","journal-title":"Bioengineered"},{"key":"10.1016\/j.drudis.2026.104800_b0570","article-title":"Lipid nanoparticle delivery system for mRNA encoding B7H3\u2010redirected bispecific antibody displays potent antitumor effects on malignant tumors","volume":"10","author":"Huang","year":"2023","journal-title":"Adv Sci"},{"key":"10.1016\/j.drudis.2026.104800_b0575","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41392-025-02343-3","article-title":"Oncolytic viruses: advanced strategies in cancer therapy","volume":"11","author":"Xiao","year":"2026","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.drudis.2026.104800_b0580","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1080\/19420862.2019.1574521","article-title":"Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies","volume":"11","author":"Trinklein","year":"2019","journal-title":"MAbs"},{"key":"10.1016\/j.drudis.2026.104800_b0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.tvr.2025.200333","article-title":"Oncolytic virus and immunogenic cell death in cancer therapy","volume":"20","author":"Cao","year":"2025","journal-title":"Tumour Virus Res"},{"key":"10.1016\/j.drudis.2026.104800_b0590","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41540-020-00145-7","article-title":"Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20\/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling","volume":"6","author":"Hosseini","year":"2020","journal-title":"npj Syst Biol Appl"},{"key":"10.1016\/j.drudis.2026.104800_b0595","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.tips.2024.12.004","article-title":"Boosting CAR-T cell therapy through vaccine synergy","volume":"46","author":"Li","year":"2025","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.drudis.2026.104800_b0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.humimm.2024.111209","article-title":"Combining anti-checkpoint immunotherapies and cancer vaccines as a novel strategy in oncological therapy: a review","volume":"86","author":"Ghaneialvar","year":"2025","journal-title":"Hum Immunol"},{"key":"10.1016\/j.drudis.2026.104800_b0605","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1035276","article-title":"Current landscape and future directions of bispecific antibodies in cancer immunotherapy","volume":"13","author":"Wei","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2026.104800_b0610","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1380142","article-title":"CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy","volume":"7","author":"Li","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.drudis.2026.104800_b0615","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005447","article-title":"Targeting CD89 on tumor-associated macrophages overcomes resistance to immune checkpoint blockade","volume":"10","author":"Xu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.drudis.2026.104800_b0620","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13036-025-00580-2","article-title":"Engineered neutrophil engagers overcome IgA limitations and reprogram resting neutrophils for cancer immunotherapy","volume":"19","author":"Lee","year":"2025","journal-title":"J Biol Eng"},{"key":"10.1016\/j.drudis.2026.104800_b0625","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2531223","article-title":"Innovative strategies for T cell engagers for cancer immunotherapy","volume":"17","author":"Bergamaschi","year":"2025","journal-title":"MAbs"},{"key":"10.1016\/j.drudis.2026.104800_b0630","doi-asserted-by":"crossref","first-page":"5394","DOI":"10.3390\/ijms26115394","article-title":"Emerging immunotherapy targets in early drug development","volume":"26","author":"Morch\u00f3n-Araujo","year":"2025","journal-title":"Int J Mol Sci"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626002059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626002059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T17:23:41Z","timestamp":1790184221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626002059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":126,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S1359644626002059"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104800","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effector-cell-engaging bispecific antibodies for cancer therapeutics: Engineering precision immunity","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104800","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104800"}}